Biotechnology

XOMA Royalty

XOMA Royalty released FY2026 Q1 earnings on May 12 (EST), actual revenue USD 12.32 M (forecast USD 13.91 M), actual EPS USD 0.17 (forecast USD 0.17)

XOMA Royalty released FY2025 Q4 earnings on March 18 Pre-Market (EST), actual revenue USD 13.76 M (forecast USD 11.05 M), actual EPS USD 0.2585 (forecast USD -0.13)

XOMA Royalty released FY2025 earnings on March 18 Pre-Market (EST), actual revenue USD 52.15 M (forecast USD 49.42 M), actual EPS USD 1.46 (forecast USD 1.166)

XOMA Royalty to release FY2025 Q4 earnings on March 18, 2026, pre-market EST; forecast revenue USD 11.05 M, EPS USD -0.13

XOMA Royalty released FY2025 9 Months Earnings on November 12 (EST), actual revenue USD 38.39 M, actual EPS USD 1.1957

XOMA Royalty released FY2025 Q3 earnings on November 12 (EST), actual revenue USD 9.351 M (forecast USD 11.47 M), actual EPS USD 0.7 (forecast USD -0.04)

XOMA Royalty released FY2025 Q2 earnings on August 13 (EST), actual revenue USD 13.13 M (forecast USD 9.388 M), actual EPS USD 0.44 (forecast USD -0.15)

XOMA Royalty released FY2025 Semi-Annual earnings on August 13 (EST), actual revenue USD 29.04 M, actual EPS USD 0.4962

XOMA Royalty released FY2025 Q1 earnings on May 13 (EST), actual revenue USD 15.91 M (forecast USD 7.065 M), actual EPS USD 0.0561 (forecast USD -0.2725)

XOMA Royalty released FY2024 annual earnings on March 17 (EST), actual revenue USD 28.49 M (forecast USD 28.53 M), actual EPS USD -1.6488 (forecast USD -1.13)

XOMA Royalty released FY2024 Q4 earnings on March 17 (EST), actual revenue 8.714 M USD (forecast 8.747 M USD), actual EPS -0.4495 USD (forecast -0.3033 USD)

XOMA Royalty released FY2024 9 Months Earnings on November 7, 2024 (EST), with actual revenue of USD 19.77 M and EPS of USD -1.1936

XOMA Royalty released FY2024 Q3 earnings on November 7, 2024 (EST), with actual revenue of 7.197 M (forecast 6.91 M) and actual EPS of -1.59 (forecast -0.415)

XOMA Royalty released FY2024 Semi-Annual earnings on August 13 (EST), actual revenue USD 12.58 M, actual EPS USD 0.4002

XOMA Royalty released FY2024 Q2 earnings on August 13 (EST), actual revenue USD 11.09 M (forecast USD 9.147 M), actual EPS USD 0.9983 (forecast USD -0.2666)

XOMA Royalty released FY2024 Q1 earnings on May 9 (EST), actual revenue USD 1.49 M (forecast USD 1.337 M), actual EPS USD -0.8603 (forecast USD -0.81)

XOMA Royalty released FY2023 annual earnings on March 8 (EST), actual revenue 4.758 M USD (forecast 6.5 M USD), actual EPS -4.04 USD (forecast -2.05 USD)

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

XOMA

District Announces Promising Water Treatment Results from Collaboration with Xoma AB | DMXCF Stock News

StockTitan

District Announces Promising Water Treatment Results from Collaboration with Xoma AB | DMXCF Stock News

LGND

Ligand Pharmaceuticals has amended its merger agreement with XOMA Royalty to include XOMA Royalty Holdings as a party. This amendment facilitates a reorganization under which Ligand's Merger Sub will merge with HoldCo, which will become a wholly owned subsidiary of Ligand. The change aims to streamline the acquisition process of XOMA Royalty.

TradingView

Ligand Pharmac-B

XOMA Corp Pref Share 8.625 Perp 12/15/21

XOMA Pref Share XOMAO 8.375 Perp 04/15/22 B

Ligand Pharmaceuticals Amends XOMA Royalty Merger Agreement to Add Holding Company

Halper Sadeh LLC is investigating XOMA, Organon & Co., and Veris Residential for potential violations of federal securities laws and breaches of fiduciary duties. The firm is concerned that insiders may benefit financially at the expense of ordinary shareholders in proposed transactions. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost. The investigations focus on XOMA's sale for $39.00 per share, Organon's sale for $14.00 per share, and Veris's sale for $19.00 per share, with the firm seeking increased consideration and disclosures on behalf of shareholders.

prnewswire

Organon

Veris Residential

17:25 ETAre XOMA, OGN, VRE Obtaining Fair Deals for their Shareholders?

SLNO

KORE

Halper Sadeh LLC is investigating Select Medical Holdings Corporation, XOMA Royalty Corporation, Soleno Therapeutics, and KORE Group Holdings for potential violations of federal securities laws and breaches of fiduciary duties. The firm is concerned that insiders may benefit financially at the expense of ordinary shareholders. Shareholders are encouraged to contact the firm to discuss their rights and options regarding the proposed sales of these companies. Halper Sadeh LLC aims to seek increased consideration and other benefits for shareholders.

Soleno Therapeutics

Select Medical

Neurocrine Biosciences

17:57 ETAre SEM, XOMA, SLNO, KORE Obtaining Fair Deals for their Shareholders?

RMAX

Class Action Attorney Juan Monteverde with Monteverde & Associates PC is investigating mergers involving Helix Energy Solutions Group (HLX), Organon & Co. (OGN), XOMA Royalty Corporation (XOMA), and RE/MAX Holdings, Inc. (RMAX). Helix shareholders will own 45% of the combined company post-merger, while Organon shareholders will receive $14.00 per share, XOMA shareholders $39.00 per share, and RE/MAX shareholders will receive either shares or $13.80 in cash. The firm has a successful track record in recovering funds for shareholders.

Helix Energy Solutions

RE/MAX

Real Brokerage

14:27 ETSHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--HLX, OGN, XOMA, and RMAX

KALV

REAX

Halper Sadeh LLC is investigating XOMA, RMAX, and KALV for potential violations of federal securities laws and breaches of fiduciary duties to shareholders. The firm is concerned that insiders may benefit financially from proposed transactions that could limit competing offers. Shareholders are encouraged to contact the firm for their rights and options regarding XOMA's sale to Ligand Pharmaceuticals, RMAX's sale to The Real Brokerage, and KALV's sale to Chiesi Group. Halper Sadeh LLC aims to seek increased consideration and other benefits for shareholders.

KalVista Pharma

14:55 ETAre XOMA, RMAX, KALV Obtaining Fair Deals for their Shareholders?

Ligand Pharmaceuticals has disclosed a 47.0% stake in XOMA Royalty Corporation through voting agreements, as part of a merger plan to acquire XOMA for $39 per share in cash plus contingent value rights. The merger agreement, filed on May 1, 2026, requires a holding company reorganization, HSR clearance, and a majority stockholder vote. Key holders representing 47% of the vote have agreed to support the deal by converting preferred shares to common shares. Ligand focuses on acquiring royalty-producing drug assets and aims to generate long-term royalty streams.

Ligand Pharmaceuticals Launches Takeover Plan at XOMA Royalty Corporation with 47.0% Stake

APPN

Top analysts downgraded Appian Corp (APPN) from Overweight to Equal-Weight with a price target cut from $41 to $25, while XOMA Royalty Corp (XOMA) was downgraded from Buy to Neutral with a $39 price target. Appian shares closed at $21.72 and XOMA shares at $40.99 on Wednesday. For more analyst opinions, visit the ratings page.

benzinga_article

Appian

This Appian Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Thursday

TEVA

CRNX

SNGX

This week's biotech news highlights significant regulatory approvals and acquisitions. Crinetics received EU approval for PALSONIFY for acromegaly, while Novartis' Rhapsido was approved for chronic spontaneous urticaria. AstraZeneca's Saphnelo Pen was cleared by the FDA for lupus treatment. Teva acquired Emalex Biosciences for $700 million, and Ligand Pharmaceuticals is set to acquire XOMA Royalty for $739 million. However, Soligenix halted its Phase 3 trial for HyBryte due to futility, while Biomea reported positive results for Icovamenib in Type 1 diabetes.

rttnews

Novartis AG

NOVARTIS AG

AstraZeneca PLC

AstraZeneca

Teva Pharmaceutical Industries

Crinetics Pharmaceuticals

Soligenix

Weekly Buzz: FDA Okays Saphnelo Pen, EC Clears Acromegaly Drug, SNGX Slumps, LGND Snaps Up XOMA

XOMA Royalty(XOMA.US)

District Announces Promising Water Treatment Results from Collaboration with Xoma AB | DMXCF Stock News

Ligand Pharmaceuticals Amends XOMA Royalty Merger Agreement to Add Holding Company

17:25 ETAre XOMA, OGN, VRE Obtaining Fair Deals for their Shareholders?

17:57 ETAre SEM, XOMA, SLNO, KORE Obtaining Fair Deals for their Shareholders?

14:27 ETSHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--HLX, OGN, XOMA, and RMAX

14:55 ETAre XOMA, RMAX, KALV Obtaining Fair Deals for their Shareholders?

Ligand Pharmaceuticals Launches Takeover Plan at XOMA Royalty Corporation with 47.0% Stake

This Appian Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Thursday

Weekly Buzz: FDA Okays Saphnelo Pen, EC Clears Acromegaly Drug, SNGX Slumps, LGND Snaps Up XOMA